David Nierengarten, Ph.D., is Managing Director and Head of Healthcare Equity Research at Wedbush Securities. He mainly covers development-stage therapeutic companies. He began his career on the financial side of biotechnology at a venture capital firm that focused on early-stage therapeutic and medical device companies. Additionally, prior to joining Wedbush, he worked in a clinical-stage, venture-backed biotechnology company, in business development and clinical trial operations. He received his bachelor’s degree in biochemistry from the University of Wisconsin-Madison and his Ph.D. in molecular and cell biology from the University of California-Berkeley.
Low Cost of Capital Sets Stage for Uptick in Biotech M&A
March 18, 2021
Seeing a Bifurcation of Therapeutic Focus in the Oncology Space
September 30, 2020
Relatively Healthy Valuations for Development-Stage Companies
October 02, 2018